Zacks.com users have recently been watching Bristol Myers (BMY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Bristol-Myers Squibb Company (NYSE:BMY ) 43rd Annual J.P. Morgan Healthcare Conference January 13, 2024 10:30 AM ET Company Participants Chris Boerner - Chairman and Chief Executive Officer Conference...

On Monday, Johnson & Johnson JNJ agreed to acquire Intra-Cellular Therapies Inc. ITCI for $132.00 per share in cash for a total equity value of approximately $14.6 billion.

When the Federal Reserve met in December, it threw the stock market and Wall Street a pretty big curveball when it revealed that the dot plot for interest rate cuts for 2025 had been lowered to just t...

Bristol Myers Squibb (BMY) concluded the recent trading session at $56.81, signifying a -0.58% move from its prior day's close.

Seven of the ten lowest-priced BBB Dogs, including Altria, Pfizer, and Verizon, are ready to buy, with dividends from $1K invested exceeding single share prices. Analysts project 16.27% to 32.98% net ...

Like a champion boxer on the ropes, Bristol-Myers Squibb (BMY -0.58%) finds itself in a challenging position. Specifically, the pharmaceutical giant's shares have declined by a disappointing 11.6% ove...

Bristol Myers stock has performed well in the past year, gaining 11%. We believe there is more room for further growth, and any dip in the share price can be used as a buying opportunity.

Large-capitalization blue-chip dividend stocks are a favorite among investors for a good reason.

If you're worried about having enough passive income to maintain your lifestyle during retirement, you're not alone. Having to spend more just to maintain their current standard of living is a constan...

Bristol Myers Squibb (BMY) closed the most recent trading day at $56.59, moving -0.35% from the previous trading session.

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb to Present at J.P. Morgan's 43rd Annual Healthcare Conference.

Bristol Myers (BMY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

The healthcare sector has long been a sanctuary for income investors seeking stability and growth. Within this realm, Bristol-Myers Squibb (BMY -2.81%) and Merck & Co. (MRK -1.33%) stand out for their...

Bristol-Myers Squibb Stock: Clearly Undervalued, Excellent 2H24 Culminates In Opdivo 'Subcu' Approval

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CheckMate--US FDA Approves Opdivo Qvantig Injection, for Subcutaneous Use in Most Previously Approved Adult, Solid Tumor Opdivo Indications.

The U.S. Food and Drug Administration said on Friday that it has approved an injectable version of Bristol Myers Squibb's blockbuster cancer drug, Opdivo.